RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials

A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells

(2016) D Sharma Das et al.   LEUKEMIA

O3.8 * Early Results: "ROCKET" a phase II Study of RRx-001, a novel triple epigenetic inhibitor, Resensitization to Irinotecan in Colorectal Cancer

(2015) C. Carter et al.   ANNALS OF ONCOLOGY

Abstract 3515: RRx-001: A double action systemically non-toxic epigenetic agent for cancer therapy

(2015) Hongjuan Zhao et al.   CANCER RESEARCH

Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study

(2015) Tony Reid et al.   LANCET ONCOLOGY

From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria

(2015) Ozlem Yalcin et al.   MALARIA JOURNAL

Macrophages and cancer: from mechanisms to therapeutic implications

(2015) Renato Ostuni et al.   TRENDS IN IMMUNOLOGY

Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001

(2015) Shoucheng Ning et al.   Oncotarget

NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001

(2015) Jan Scicinski et al.   Redox Biology

Abstract 1420: RRx-001 inhibits glucose erythrocyte and tumor glucose 6-phosphate dehydrogenase

(2015) Pedro Cabrales et al.   CANCER RESEARCH

Episensitization: Therapeutic Tumor Resensitization by Epigenetic Agents: A Review and Reassessment

(2014) Bryan Oronsky et al.   Anti-Cancer Agents in Medicinal Chemistry

The Capacity of Red Blood Cells to Reduce Nitrite Determines Nitric Oxide Generation under Hypoxic Conditions

(2014) Marcel H. Fens et al.   PLoS One

The Scarlet Letter of Alkylation: A Mini Review of Selective Alkylating Agents

(2014) Bryan T. Oronsky et al.   Translational Oncology

Development of methods for the bioanalysis of RRx-001 and metabolites

(2014) Jan Scicinski et al.   Bioanalysis

Understanding, recognizing, and managing toxicities of targeted anticancer therapies

(2013) Grace K. Dy et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Oxidized Low-Density Lipoprotein Induces Inflammatory Responses in Cultured Human Mast Cells Via Toll-Like Receptor 4

(2013) Zhe Meng et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Abstract 4371: RRx-001 modulates intratumor blood flow in SCCVII and U87 tumors

(2012) Jan Scicinski et al.   CANCER RESEARCH

Dinitroazetidines Are a Novel Class of Anticancer Agents and Hypoxia-Activated Radiation Sensitizers Developed from Highly Energetic Materials

(2012) S. Ning et al.   CANCER RESEARCH

How cancer metabolism is tuned for proliferation and vulnerable to disruption

(2012) Almut Schulze et al.   NATURE

Development of a Safe and Efficient Two-Step Synthesis for Preparing 1-Bromoacetyl-3,3-dinitroazetidine, a Novel Clinical Anticancer Candidate

(2012) Nicholas A. Straessler et al.   ORGANIC PROCESS RESEARCH & DEVELOPMENT

Mechanisms of drug resistance in kinases

(2011) Rina Barouch-Bentov et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

A role for activated endothelial cells in red blood cell clearance: implications for vasopathology

(2011) M. H. A. M. Fens et al.   HAEMATOLOGICA

How were new medicines discovered?

(2011) David C. Swinney et al.   NATURE REVIEWS DRUG DISCOVERY

Microvascular endothelial cells express a phosphatidylserine receptor: a functionally active receptor for phosphatidylserine-positive erythrocytes

(2007) B. N. Y. Setty et al.   BLOOD